RAP1A AND RAP1B IN THE DIAGNOSIS AND TMT - ORAL CANCER

候选人：博士后期间参与过临床相关基础科学研究。这种训练和候选人对混杂的临床病理问题的理解有助于她致力于口腔癌的转化研究。近期目标是国际知名的临床医生-科学家。长期目标是成为一名独立的转化科学家，能够弥合实验室工作台和患者护理之间的差距。环境：密歇根大学为临床科学家提供了良好的培养环境。癌症中心因其在临床和生物医学研究方面的开创性工作而享誉国际。基础科学知识的发展转化为对病人护理的改进。研究职业发展计划：该计划包括5年的奖励期，包括受监督的基础科学和转化研究轮转、头颈癌专题讨论会、每周信号、研究责任和伦理。研究项目：本提案的总体目标是加强对口腔癌分子选择的理解。Rap1是一种ras样蛋白，将被评估为人类口腔癌前上皮病变恶性转化的预测性生物标志物。此外，rap1B， rap1亚型，将被评估为预后预测的候选蛋白，当用作鳞状细胞癌（SCC）转移潜力的生物标志物时。这将允许识别病变，应该更积极地治疗。第三部分涉及一个方案的设计，以研究rap1A在基因治疗中治疗残留上皮发育不良或鳞状细胞癌病变的使用。

Candidate: The candidate has been involved in clinically relevant basic science research during the post-doctoral studies. This training and the candidate's understanding of confounding clinico-pathologic issues have contributed to her commitment to pursue translational research in oral cancer. The immediate goal is internationally renowned clinician- scientists. The long-term goal is to become an independent translational scientist capable of bridging the gap between the laboratory bench and patient care. Environment: The University of Michigan is a nurturing environment for the clinician-scientist. The Cancer Center is internationally reputed for its pioneering work in clinical and biomedical research. The developments in basic science knowledge are translated into improvements in patient care. Research Career Development Plant: The plan encompasses the 5 year award period and includes supervised basic science and translational research rotations, Head and Neck Cancer Symposia, weekly signaling, research responsibility and ethics. Research Project: The overall objective of this proposal is to enhance the understanding of the molecular choices of oral cancer. Rap1, a ras-like protein, will be evaluated as a predictive biomarker for malignant transformation of precancerous human oral epithelial lesions. Additionally, a rap1B, a rap1 isoform, will be assessed as a candidate protein for prognosis prediction, when used as a biomarker for metastatic potential of squamous cell carcinoma (SCC). This would allow the identification of lesions that should be treated more aggressively. The third segment involves the design of a protocol to investigate the use of rap1A in gene therapy to treat residual epithelial dysplasia or squamous cell carcinoma lesions.